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• Acute myeloid leukemia (AML) is characterized by proliferation of
immature myeloid cells in the bone marrow and primarily affects
older adults (median age of diagnosis of 69 years)1
• Guideline-based treatment options for AML depend on patients’ age,
performance status, and adverse features such as unfavorable
cytogenetics or molecular markers, and comorbidities1
• Response and tolerability to standard AML therapy [7 days of
cytarabine plus 3 days of an anthracycline (7+3)] is reduced in elderly
patients; alternative treatment options include monotherapy with
hypomethylating agents (HMA) such as azacitidine or decitabine,
however, use of these agents alone are associated with poorer
response rates 2
• Venetoclax, an oral BCL-2 inhibitor, is FDA approved in combination
with HMAs or low-dose cytarabine for the treatment of newly-
diagnosed AML in adults 75 years or older, or patients with
comorbidities that preclude the use of intensive induction
chemotherapy3,4
• Venetoclax + HMAs has been associated with 61% complete
remission (CR)/ complete remission with incomplete count recovery
(CRi) rates in treatment-naïve older adults3,4
• Guidelines support the use of venetoclax in combination with HMAs
or low dose cytarabine for patients ages 60 and older with
unfavorable risk cytogenetics that are candidates for intensive
remission induction therapy1
Evaluate the outcomes of AML induction regimens in patients 60 years
or older with unfavorable risk cytogenetics that are candidates for
intensive remission induction therapy at a community hospital
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Discussion
Observations:
• There was no statistically significant difference between the CR rates
and RFS of the high and low intensity groups
• Significantly less grade 3/4 toxicities noted in low intensity group
when compared to high intensity
• Rate of CR/CRi in venetoclax + HMA study cohorts is similar to those
reported in studies
• Febrile neutropenia was the most commonly observed toxicity in all
groups followed by grade 4 thrombocytopenia
• 2 patients were lost to follow up
Limitations of study design:
• Single center study
• Retrospective study creates potential for selection bias
• Lack of thorough documentation in the electronic medical record,
particularly as is relates to baseline ECOG status and determining if
toxicities were treatment-related or disease-related
• Low volume of patients due to extensive inclusion/exclusion criteria
and inconsistent number of patients per treatment group prevents
meaningful comparison between individual groups
• Unable to assess adherence to oral therapies (venetoclax) and
determine effect of potential drug-drug interactions
• Provider utilization of decitabine 5-day vs. 10-day regimen not
standardized
• Short duration of follow up (ongoing)
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Conclusion
In this review, CR rates among the different regimens recommended for
elderly AML patients were comparable, with more toxicities being
observed with the more intensive regimens containing anthracyclines.
Further larger studies are needed to be able to more accurately compare
the regimens in terms of efficacy and toxicity.
Methods
• Design: Single-center, IRB-approved, retrospective chart review
• Evaluation period: February 1st, 2018 - August 1st, 2019
• Primary outcomes: Rate of complete morphologic remission +
complete morphologic remission with incomplete count recovery
(CR/CRi)*
• Secondary outcomes: Rate of induction failure*, relapse free survival
(RFS)*, time to CR/CRi, hospital length of stay (LOS), percentage of
patients who went on to receive transplant, grade 1-5 treatment-
related toxicities**
• Inclusion criteria: Age 60 or older at start of treatment, admitted to
hospital oncology inpatient unit, confirmed AML diagnosis,
unfavorable risk cytogenetics
• Regimens studied: cytarabine/daunorubicin (7+3 reference group);
liposomal daunorubicin/cytarabine for therapy-related AML (CPX-351
reference group); venetoclax/decitabine (VEN+DEC); venetoclax/
azacitidine (VEN+AZA); venetoclax/low dose cytarabine (VEN+LoDAC)
• Exclusion criteria: Received prior therapy for AML
• Procedure: Patients identified using ICD 10 AML diagnosis codes;
Fischer’s exact test (categorical) and unpaired t test (continuous) used
to determine statistical significance at an alpha of 0.05
*Outcomes defined by International Working Group response criteria for AML
**Toxicities graded using National Cancer Institute Common Terminology Criteria for
Adverse Event [CTCAE] Version 5.0
FN	=	febrile	neutropenia
NS	=	not	significant
Patient	Characteristics		 N=20
Mean	age,	years
Age	60-74
Age	75+
74
45% (9)
55% (11)
Gender,	female 50% (10)
Diagnoses
• AML
• AML	from	MDS
50% (10)
50%	(10)
Baseline	ECOG	status	
• 0	
• 1
• 2
• Not	documented	
25% (5)
25% (5)
5% (1)
45% (9)
Regimen Rate of	
CR/CRi
Rate	of	
induction	
failure
Median time	
to	CR/CRi
(days)
Median	RFS	
(days)
Median
LOS	(days)
Transplant	
eligible
Received
transplant
High	Intensity (n=12) 75%	(9) 25%	(3) 26 272 33 58%	(7) 8%	(1)
• 7+3		(n=9) 78%	(7) 22%	(2) 26 283 34 67%	(6) 11%	(1)
• CPX-351	(n=3)	 67%	(2) 33%	(1) 32 530 40 33%	(1) 0
Low	Intensity	(n=8) 63% (5) 37% (3) 23 223 26 63%	(5) 0
• VEN+DEC	(n=5) 60%	(3) 40%	(2) 25.5 184 29 60%	(3) 0
• VEN+AZA	(n=3)	 67%	(2) 33%	(1) 23 357 17 67%	(2) 0
45% 
15% 
20% 
15% 
Regimens
7+3	(n=9) CPX-351	(n=3) 
VEN+DEC	(n=5) VEN+AZA	(n=3) 
VEN+LoDAC	(n=0)
Patient	Characteristics	 N=20
Mutations	Found
TP53
RUNX1
ASXL1
GATA2
FLT3
IDH1/2
NPM1
DNMT3A
STAG2
Del	(7q)
Del	(5q)	
Del	(17p)
Complex	karyotype	
20% (4)
10%(2)
5% (1)
10%	(2)
25%	(5)
20%	(4)
25%	(5)
40%	(8)
20%(4)
10% (2)
10% (2)
10% (2)
40% (8)
Regimen Median	duration	of	neutropenia
(days)
Median	duration	of	thrombocytopenia
(days)	
High	Intensity (n=12) 30 31
• 7+3		(n=9) 27 23
• CPX-351	(n=3)	 30 32
Low	Intensity	(n=8) 34 32
• VEN+DEC	(n=5) 38 18
• VEN+AZA	(n=3)	 30 38
Outcome High	intensity	(n=12) Low	Intensity (n=8) P	value
CR/CRi rates 75% 63% 0.0922	(NS)
Median	RFS 272	days 223	days	 0.1496	(NS)
Grade	3/4 toxicities 100% 88% 0.0003
Treatment-related toxicities High	intensity	(n=12) Low	intensity	(n=8)
Any-grade	toxicities 100% (12) 88% (7)
Grade	3/4	toxicities	 100%	(12) 88% (7)
Grade	3	FN 92% (11)	 75% (6)	
Grade	4	thrombocytopenia	 92% 11) 88% (7)	
Grade	1/2	AST	or	ALT	increase	 42% (5) 25% (2)
Grade	1/2		SCr increase	 8% (1) 0
Grade	3	cardiotoxicity	 8% (1) 0	
